Skip to main content
Category

News

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

By News
Ingelheim, Germany and South San Francisco, Calif., USA — 4 January 2023 — Boehringer Ingelheim and 3T Biosciences (“3T”) today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies. Despite the significant transformation of the cancer treatment landscape…
Read More

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic

By News
Highly respected T-cell immunologist brings more than three decades’ experience working across diverse R&D disciplines in T-cell immunology and cancer biology Joining forces is Estelle Marrer-Berger, Ph.D., as chief development officer SOUTH SAN FRANCISCO, Calif., October 25, 2023 – 3T Biosciences (“3T”), an immunotherapy company changing the future of treatment…
Read More

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

By News
INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., USA, 9 January 2023 – Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class…
Read More

3T Biosciences Debuts with $40 Million Series A Financing

By News
Immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations Company secured exclusive license with Stanford University for novel TCR-mimetic discovery platform and development stage MAGE-A3 TCRs Stefan Scherer, M.D., Ph.D., named president and CEO, and Christopher DeRespino, MBA, appointed…
Read More